ArticleAmerican journal of translational research2025
Erianin inhibits endometrial cancer cell proliferation and migration by modulating glutamine metabolism through the ERK signaling pathway.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacological activity, molecular mechanisms and therapeutic potential of erianin (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the therapeutic use of erianin, a bioactive compound derived from traditional Chinese medicine, in the treatment of EC and its regulatory effects on glutamine metabolism.
methodsHuman Endometrial cancer (EC) cell lines, HEC-1A and Ishikawa, were exposed to erianin, and cellular proliferation and migratory capacity were assessed using the Cell Counting Kit-8 (CCK-8) assay and the Transwell migration assay, respectively. Glutamine metabolism was evaluated by quantifying intracellular glutamine, α-ketoglutaric acid (α-KG), and adenosine triphosphate (ATP). A xenograft tumor model was used to validate the antitumor efficacy of erianin
resultsErianin treatment significantly inhibited the proliferation and migration of EC cells
conclusionErianin inhibits glutamine metabolism and suppresses the growth of EC through the ERK signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.